Noticias y Actividades de Monte Rosa Therapeutics

Monte Rosa Therapeutics es una de las ...

• Russell 3000;
• TOB Iconic 10,000.

Monte Rosa Therapeutics es una empresa que cotiza bajo el símbolo de cotización GLUE (US).

Ver el organigrama con sus 23 ejecutivos principales

Biografías más buscadas en Monte Rosa Therapeutics

• Markus Warmuth, Chief Executive Officer and Director
• Eric Hughes, Director
• Chandra Leo, Director

Crear su alerta
para seguir los movimientos de los ejecutivos en Monte Rosa Therapeutics.

Monte Rosa Therapeutics tiene 2.405 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y BioNTech (Alemania).

Popular M&A news in Biotecnología

• IMU Biosciences acaba de anunciar una recaudación de fondos de 53 millones de dólares. (publicado el 3 de junio de 2026).
• NewLimit acaba de anunciar una recaudación de fondos de 435 millones de dólares. (publicado el 3 de junio de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado el 1 de junio de 2026)..

Otros contactos sugeridos en el sector Biotecnología

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer en Inceptive
• Jan Van de Winkel - President and Chief Executive Officer en Genmab
• Valerie Hanote - Non-Executive Director en Eurofins

Saber más sobre el sector Biotecnología

Últimos comunicados de prensa de Monte Rosa Therapeutics

• Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference - Monte Rosa Therapeutics
• Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates - Monte Rosa Therapeutics
• Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs - Monte Rosa Therapeutics
• Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025 - Monte Rosa Therapeutics
• Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - Monte Rosa Therapeutics
• Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025 - Monte Rosa Therapeutics
• Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Monte Rosa Therapeutics
• Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer - Monte Rosa Therapeutics
• Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - Monte Rosa Therapeutics
• Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors - Monte Rosa Therapeutics
• View more press releases Close

Redes sociales sobre Monte Rosa Therapeutics

• Monte Rosa Therapeutics en Wikipedia, Google News y Yahoo Finance
• Monte Rosa Therapeutics en LinkedIn, Twitter y YouTube